Form 4: Compass Pathways Director George Jay Goldsmith Reports Share Sales

George Jay Goldsmith, a director at Compass Pathways plc, reported the sale of ordinary shares on May 20 and May 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• George Jay Goldsmith, a director of Compass Pathways plc, filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2024, Goldsmith sold 6,703 ordinary shares at a weighted average price of $7.892, with prices ranging from $7.80 to $7.99.
• On the same day, his spouse sold 6,704 ordinary shares at the same weighted average price.
• On May 21, 2024, Goldsmith sold 8,900 ordinary shares at a weighted average price of $7.9078, with prices ranging from $7.83 to $8.03.
• Also on May 21, 2024, his spouse sold 8,900 ordinary shares at the same weighted average price.
• The sales were executed automatically under a Rule 10b5-1 trading plan adopted on August 23, 2023.
• Following these transactions, Goldsmith directly owns 3,931,687 shares and his spouse indirectly owns 3,929,413 shares.
• Goldsmith and his spouse disclaim beneficial ownership of each other's shares.

Sentiment

Score: 5

Explanation: The document is a routine filing related to pre-planned share sales. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Sales by insiders are common and often pre-planned, but investors may scrutinize the timing and volume of sales for signals about the company's prospects.

Comparison to Industry Standards

• Comparing insider trading activity to similar biotech companies like MindMed or Atai Life Sciences could provide context.
• Monitoring the volume of shares sold as a percentage of total outstanding shares can be compared to industry benchmarks for insider selling.

Stakeholder Impact

• Shareholders may react to insider selling, although pre-planned sales are generally less concerning.
• The impact on other stakeholders is likely minimal, as these are standard transactions.

Key Dates